AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05403086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
Study NCT05730621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate Sustained Release/Aspirin
Description: Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
Study NCT05730621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd for 12 weeks
Study NCT05211895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (Intravenous infusion)
Study NCT05211895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab IV (Intravenous infusion)
Study NCT05211895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab IV (Intravenous infusion)
Study NCT05211895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo IV (Intravenous infusion)
Study NCT06194188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of CU-20401
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
Study NCT06194188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous injection of CU-20401
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
Study NCT05766943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Pass ON
Description: Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
Study NCT05766943 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smart Pass OFF
Description: Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
Study NCT05514054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.
Study NCT05514054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Administered per local approved label.
Study NCT05514054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Administered per local approved label.
Study NCT05514054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Administered per local approved label.
Study NCT05514054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered per local approved label.
Study NCT05993546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum assisted sheath
Description: allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
Study NCT05993546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive suction via conventional sheath
Description: conventional access sheath for stone retrieval using current technique via passive suction
Study NCT04937387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI
Description: FF/VI will be administered.
Study NCT04937387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered.
Study NCT04937387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Study NCT04643041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watch and wait
Description: patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
Study NCT05044247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP blocks
Description: ultrasound and fluoroscopy to identify the spread of drug
Study NCT05545423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented assisted soft tissue mobilization
Description: the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
Study NCT05545423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
Study NCT05545423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
Study NCT04998162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF injection
Description: Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
Study NCT06175039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
Study NCT06175039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control program
Description: KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
Study NCT05323877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Device (PerQseal+)
Description: Percutaneous arterial closure device
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNFa Antagonist - Infliximab
Description: • Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNFa Antagonist - Adalimumab
Description: • Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IL12/23 or anti-IL23 - Ustekinumab
Description: • Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IL12/23 or anti-IL23 - Risankizumab
Description: • Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-integrin - Vedolizumab IV
Description: • Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
Study NCT05928039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-integrin - Vedolizumab IV and SC
Description: • Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
Study NCT05477004 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
Study NCT05238688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) group
Description: Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
Study NCT05238688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group
Description: Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
Study NCT05555277 — intervention group
Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
Study NCT05789056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRX003, 4% Lotion
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Study NCT04993209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 1μg
Description: NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
Study NCT04993209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 3μg
Description: NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
Study NCT04993209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
Study NCT04993209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed inactivated COVID-19 vaccine (CoronaVac)
Description: Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
Study NCT06652789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene
Description: The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call.
Study NCT06652802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.
Description: * An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it.
Study NCT06652802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-Conducted Brief Intervention (NCBI)
Description: * Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members.
Study NCT04678843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Family-Based Treatment
Description: Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
Study NCT05198856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Combined With Chemotherapy and Monotherapy
Description: Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions.
Study NCT05807971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-063
Description: 12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
Study NCT05303129 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
Study NCT05758402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice group
Description: Routine practice group
Study NCT05758402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EARP group
Description: EARP group
Study NCT06085716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention
Description: Participants in the PI group will complete the educational sessions only.
Study NCT05807971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsule to the drug without the active ingredient.
Study NCT06347367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)
Description: Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
Study NCT06347367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)
Description: İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
Study NCT06085716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Placebo
Description: This group will only take placebo capsules every day.
Study NCT06085716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention+Placebo
Description: This group will take the placebo capsules every day, as well as completing the educational sessions.
Study NCT06300099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone as adjunct to serratus anterior plane block.
Study NCT06300099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine as adjunct to serratus anterior plane block.
Study NCT04600336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride
Description: Given PO
Study NCT04600336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT04600336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04600336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04600336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04600336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06024993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Description: 20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
Study NCT06024993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional volume-controlled ventilation (VCV)
Description: 20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
Study NCT06594913 — intervention group
Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
Study NCT06656104 — intervention group
Intervention type: DEVICE
Intervention: Reference strategy
Description: Routine strategy based on the usual catheters and infusion systems used during the reference period
Study NCT06656104 — intervention group
Intervention type: DEVICE
Intervention: Experimental strategy
Description: EDELVAISS multi-infusion strategy as routine strategy during the experimental period
Study NCT04626362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.
Study NCT04626362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo juice
Description: Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
Study NCT06651632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquablation Therapy
Description: The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
Study NCT06651632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
Study NCT06604364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypno VR
Description: pre-surgery sedation using virtual reality headset
Study NCT06655220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride
Study NCT06655220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368